Royalty Pharma (RPRX) EVP & CFO Terrance Coyne Sells Shares

What Happened
Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, sold a total of 11,002 Class A ordinary shares in open-market transactions on August 13, 2026, for aggregate proceeds of about $645,551. The sales were reported as two blocks: 9,230 shares at a weighted average price of $58.59 (≈ $540,752) and 1,772 shares at a weighted average price of $59.14 (≈ $104,799). These were sales (not purchases) and thus generally reflect disposition of holdings rather than a bullish insider purchase.

Key Details

• Transaction date: August 13, 2026 (filed August 17, 2026). Filing appears to be within the SEC’s 2-business-day window.
• Sales: 9,230 shares @ $58.59 (weighted avg; prices in that block ranged $57.99–$58.98) and 1,772 shares @ $59.14 (weighted avg; prices in that block ranged $58.98–$59.52). (Footnotes F2 & F3 offer breakdowns on request.)
• Total shares sold: 11,002; total proceeds ≈ $645,551.
• Plan/authorization: All reported transactions were effected pursuant to a 10b5-1 trading plan adopted February 24, 2026 (Footnote F1).
• Post-transaction holdings: The filing’s remarks note additional interests — the Reporting Person and family vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A shares and Class E shares of RPH exchangeable into 1,788,777 Class A shares (Class E shares subject to vesting). The filing does not list a simple direct post-sale share count in the provided summary.

Context

• 10b5-1 plan: Sales under a pre-established 10b5-1 plan are scheduled trades and are often treated as routine rebalancing/liquidity events rather than immediate signals of management sentiment.
• Sale code: These were Code “S” transactions (open-market sales).
• No options exercised or awards involved in these reported transactions.